Currently, ongoing clinical trials evaluating combination therapy with capmatinib, including amivantamab, trametinib, and immunotherapy, are being conducted to improve efficacy and broaden indications of capmatinib with new drug agents such as antibody–drug conjugates being developed to treat MET dysregulated NSCLC. The gene discussed is MET; the disease is non-small cell lung carcinoma.